TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25428435

Group type: EXPERIMENTAL
Intervention: Supernatant embryo culture fluid (SEET)
Number of subjects: 60
Study: 23204168

Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02(A) malaria vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21820244

Group type: EXPERIMENTAL
Intervention: DVD plus information booklet (n=57)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Booklet only (n=51)
Number of subjects: 108
Study: 19694381

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg once a day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg once a day) + Tolterodine (2 mg twice a day)
Number of subjects: 53
Study: 16476220

Group type: EXPERIMENTAL
Intervention: Long-term insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose control
Number of subjects: 0
Study: 15470173

Group type: EXPERIMENTAL
Intervention: Desflurane 1 MAC, administered 30 min prior to the end of the surgical procedure.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol (control group).
Number of subjects: 30
Study: 11304776

Group type: EXPERIMENTAL
Intervention: Epirubicin (110 mg/m²) followed by paclitaxel (225 mg/m²) every 2 weeks for four cycles each, with granulocyte colony-stimulating factor support (Group A)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Epirubicin (80 mg/m²) followed by paclitaxel (175 mg/m²) every 3 weeks for six cycles (Group B)
Number of subjects: 183
Study: 9103390

Group type: EXPERIMENTAL
Intervention: Patients with gynecological cancers
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 220

Group type: COMPARATOR
Intervention: General public (healthy women)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Formal education
Number of subjects: 220
Study: 7506170

Group type: EXPERIMENTAL
Intervention: nimesulide (100mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: diclofenac (50mg twice daily)
Number of subjects: 50
Study: 3318259

Group type: EXPERIMENTAL
Intervention: Insulin + glipizide (3 X 10 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 10
Study: 31973765

Group type: EXPERIMENTAL
Intervention: Communication skills training for physicians (3 sessions of Focus-Group Discussion and 2 workshops)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 240
Study: 29402848

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (lifestyle changes only)
Number of subjects: 106
Study: 26259808

Group type: EXPERIMENTAL
Intervention: labetalol (less tight control)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: labetalol (tight control)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: methyldopa (less tight control)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: methyldopa (tight control)
Number of subjects: 987
Study: 25199613

Group type: EXPERIMENTAL
Intervention: GCS scoring aid
Number of subjects: 178

Group type: COMPARATOR
Intervention: No GCS scoring aid
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Overall accuracy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Subcomponent accuracy
Number of subjects: 178
Study: 22571553

Group type: EXPERIMENTAL
Intervention: Social support and social network characteristics
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Number of smokers in the social network
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Partner smoking
Number of subjects: 151
Study: 20575195

Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) porcelain brackets on anterior teeth and SL metal brackets on posterior teeth
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional porcelain (CP) brackets tied with ligatures on anterior teeth and conventional metal brackets on posterior teeth
Number of subjects: 60
Study: 19047916

Group type: EXPERIMENTAL
Intervention: Prenatal drug exposure (PDE) children remaining in maternal care
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Prenatal drug exposure (PDE) children in nonmaternal care
Number of subjects: 144

Group type: COMPARATOR
Intervention: Community comparison (CC) children
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: CPT errors of omission and commission
Number of subjects: 144
Study: 16178830

Group type: EXPERIMENTAL
Intervention: Self-directed learning (computer-assisted)
Number of subjects: 175
Study: 14578832

Group type: EXPERIMENTAL
Intervention: High-dose midazolam (1 mg/kg, HDM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard-dose midazolam (0.5 mg/kg, SDM)
Number of subjects: 65
Study: 11051305

Group type: COMPARATOR
Intervention: Simulated altitude of 0 m
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 1200 m
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 2400 m
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 3700 m
Number of subjects: 4
Study: 8840841

Group type: EXPERIMENTAL
Intervention: Ambulatory ECG (AECG) monitoring
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Exercise treadmill test (ETT)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Correlation between ETT and AECG
Number of subjects: 910
Study: 1371225

Group type: EXPERIMENTAL
Intervention: Laser grid photocoagulation for retinal pigment epithelial detachment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated lesions (control group)
Number of subjects: 0
Study: 6570116

Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g) intravenously at the time of induction of anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without the antibiotic
Number of subjects: 60
Study: 29282989

Group type: EXPERIMENTAL
Intervention: Therapeutic companion robot (PARO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Look-alike plush toy and usual care
Number of subjects: 5
Study: 30205746

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 3 mg BMS-986165 every other day
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 3 mg BMS-986165 daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 3 mg BMS-986165 twice daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 6 mg BMS-986165 twice daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 12 mg BMS-986165 daily
Number of subjects: 267
Study: 27454263

Group type: EXPERIMENTAL
Intervention: Ibuprofen 50 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.25 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ibuprofen 25 mg + Hydromorphone 0.125 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ibuprofen and Hydromorphone combination
Number of subjects: 90
Study: 24599110

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control (INT)
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Baseline C-peptide
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Poor glucose control at baseline
Number of subjects: 858
Study: 22043837

Group type: EXPERIMENTAL
Intervention: Integration of HIV care services including HAART into ANC clinics
Number of subjects: 36
Study: 21194605

Group type: COMPARATOR
Intervention: Levetiracetam 250 mg administered as an immediate-release tablet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Levetiracetam delivered in the proximal small bowel
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Levetiracetam delivered in the distal small bowel
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Levetiracetam delivered in the ascending colon
Number of subjects: 9
Study: 17497175

Group type: EXPERIMENTAL
Intervention: COMT Ex4‐76C > G (Leu136Leu) polymorphism
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: COMT haplotypes including variant allele for COMT Ex4‐76 C > G
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: COMT polymorphisms
Number of subjects: 2371
Study: 16220801

Group type: EXPERIMENTAL
Intervention: Water‐activated zinc polycarboxylate cement with 0.12% chlorhexidine gluconate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water‐activated zinc polycarboxylate cement (control group)
Number of subjects: 9
Study: 12118903

Group type: EXPERIMENTAL
Intervention: Darusentan 10 mg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Darusentan 30 mg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Darusentan 100 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 11332870

Group type: EXPERIMENTAL
Intervention: Piracetam treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 9071195

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isradipine and Atenolol
Number of subjects: 24
Study: 8201928

Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg daily or Ciprofloxacin 1000 mg daily
Number of subjects: 14
Study: 3493903

Group type: EXPERIMENTAL
Intervention: High dose MTX (regimen I)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Moderate dose MTX (regimen II)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (both regimens)
Number of subjects: 106
Study: 29329979

Group type: EXPERIMENTAL
Intervention: Stress induction using the socially evaluated cold‐pressor test (SECPT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 53
Study: 27733165

Group type: EXPERIMENTAL
Intervention: ibuprofen 400 mg PO and metoclopramide 10 mg PO
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: tramadol 50 mg PO
Number of subjects: 576

Group type: COMPARATOR
Intervention: placebo (two placebo pills)
Number of subjects: 576
Study: 23558663

Group type: EXPERIMENTAL
Intervention: Radiographic assessment of femoral implant position
Number of subjects: 40
Study: 23579897

Group type: EXPERIMENTAL
Intervention: Electric torque-control motor
Number of subjects: 26

Group type: COMPARATOR
Intervention: Air-driven handpiece
Number of subjects: 26
Study: 20546277

Group type: EXPERIMENTAL
Intervention: Culturally appropriate health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual health education
Number of subjects: 0
Study: 18936219

Group type: EXPERIMENTAL
Intervention: C+P (carbohydrate and protein hydrolysate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: W (water only)
Number of subjects: 20
Study: 16729918

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) in addition to mebeverine hydrochloride
Number of subjects: 149

Group type: COMPARATOR
Intervention: mebeverine hydrochloride alone
Number of subjects: 149
Study: 14671984

Group type: EXPERIMENTAL
Intervention: 6-week interval between INR determinations (group 1)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 4-week interval between INR determinations (group 2, control)
Number of subjects: 124
Study: 10992533

Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous spray 200 microgram once daily (first season)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (first season)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Beclomethasone 200 microgram twice daily (second season)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Fluticasone (second season)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (second season)
Number of subjects: 97
Study: 8792038

Group type: EXPERIMENTAL
Intervention: Oral magnesium 600 mg (24 mmol) daily for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 1377035

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (GpI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Autologous fresh whole blood transfusion (GpII)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (GpIII)
Number of subjects: 90
Study: 29248399

Group type: EXPERIMENTAL
Intervention: Palliative chemoradiotherapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 220
Study: 27472271

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-IBD patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural products
Number of subjects: 0
Study: 23399046

Group type: EXPERIMENTAL
Intervention: Insertion torque ≤20 Ncm
Number of subjects: 21

Group type: COMPARATOR
Intervention: Insertion torque >50 Ncm
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Machined implant neck design
Number of subjects: 21

Group type: COMPARATOR
Intervention: Anodized implant neck design
Number of subjects: 21
Study: 22827973

Group type: EXPERIMENTAL
Intervention: Polyphenon E (Poly E) 400 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polyphenon E (Poly E) 600 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polyphenon E (Poly E) 800 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20845296

Group type: EXPERIMENTAL
Intervention: L‐carnitine 25 mg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 2 gr/day
Number of subjects: 52
Study: 18665162

Group type: EXPERIMENTAL
Intervention: Dietary intake of thiamin, riboflavin, niacin, folate, methionine, and alcohol
Number of subjects: 4260

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 4260
Study: 16200756

Group type: EXPERIMENTAL
Intervention: EMG-triggered robot-assisted therapy
Number of subjects: 0
Study: 14571302

Group type: EXPERIMENTAL
Intervention: Ezetimibe (cholesterol absorption inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe in combination with atorvastatin or simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 0
Study: 10770363

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg, 5 injections over 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (5 injections over 3 months)
Number of subjects: 40
Study: 8901790

Group type: EXPERIMENTAL
Intervention: Diet containing 300 g shrimp/d (590 mg dietary cholesterol/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet containing two large eggs per day (581 mg dietary cholesterol/d)
Number of subjects: 0
Study: 1829300

Group type: EXPERIMENTAL
Intervention: Ranitidine (2 x 150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucralfate (4 x 1 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg for 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6824555

Group type: EXPERIMENTAL
Intervention: Mianserin (Bolvidon‐Organon)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxepin (Sinequan‐Pfizer)
Number of subjects: 60
Study: 30739941

Group type: EXPERIMENTAL
Intervention: Subcostal TAP block with 10 mL of 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Port site infiltration with local anesthetic
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcostal TAP block
Number of subjects: 60
Study: 30369310

Group type: EXPERIMENTAL
Intervention: Levosimendan (loading dose 12 μg/kg + 0.1 μg/kg per minute)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dobutamine (7.5 μg/kg per minute)
Number of subjects: 32
Study: 25362579

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus‐eluting stent (R‐ZES)
Number of subjects: 20
Study: 25280761

Group type: EXPERIMENTAL
Intervention: Stress MBF and MFR measurements using (99m)Tc-sestamibi dynamic SPECT imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intra-operator variability measurements by expert and novice operators
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inter-operator variability measurements
Number of subjects: 28
Study: 21228025

Group type: EXPERIMENTAL
Intervention: subcutaneous interferon beta-1a (44 mcg three times weekly)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: intramuscular interferon beta-1a (30 mcg weekly)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: glatiramer acetate (20 mg daily)
Number of subjects: 165

Group type: COMPARATOR
Intervention: untreated patients (reference population)
Number of subjects: 165
Study: 20819471

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate for 2 weeks after ESS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 16428941

Group type: EXPERIMENTAL
Intervention: Metopimazine (7.5 mg x 2 t.i.d.)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ondansetron (8 mg b.i.d.)
Number of subjects: 200
Study: 12937336

Group type: EXPERIMENTAL
Intervention: Coping With Caregiving psychoeducational program
Number of subjects: 213

Group type: COMPARATOR
Intervention: Enhanced Support Group condition
Number of subjects: 213
Study: 11079649

Group type: EXPERIMENTAL
Intervention: Immediate availability of myoglobin/CK-MB results at 0 and 1 hour after enrollment (stat)
Number of subjects: 6352

Group type: COMPARATOR
Intervention: Conventional reporting of myoglobin/CK-MB 3 hours or more after hospital admission (control)
Number of subjects: 6352

Group type: EXPERIMENTAL
Intervention: Immediate availability of myoglobin/CK-MB results (stat)
Number of subjects: 6352

Group type: COMPARATOR
Intervention: Conventional reporting of myoglobin/CK-MB (control)
Number of subjects: 6352
Study: 9051024

Group type: EXPERIMENTAL
Intervention: Portal venous flow measurement by sonographers
Number of subjects: 5
Study: 1585407

Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fed condition
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of fasted and fed conditions
Number of subjects: 17
Study: 2865674

Group type: EXPERIMENTAL
Intervention: Bypass surgery joining the superficial temporal artery and the middle cerebral artery
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Best medical care
Number of subjects: 1377
Study: 31631248

Group type: EXPERIMENTAL
Intervention: Letrozole step-up protocol (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Letrozole plus hMG (Group B)
Number of subjects: 60
Study: 29026170

Group type: EXPERIMENTAL
Intervention: High dose AN-PEP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low dose AN-PEP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26530933

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and low-GI diets
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-carbohydrate and high-GI diets
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diets varying in carbohydrate and glycemic index
Number of subjects: 91
Study: 23891460

Group type: EXPERIMENTAL
Intervention: Telephone brief intervention (n=68)
Number of subjects: 131

Group type: COMPARATOR
Intervention: In-person brief intervention (n=63)
Number of subjects: 131
Study: 21898717

Group type: EXPERIMENTAL
Intervention: Augmentation with buspirone
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Switching to venlafaxine
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Switching to bupropion
Number of subjects: 269

Group type: COMPARATOR
Intervention: Augmentation strategy
Number of subjects: 269

Group type: COMPARATOR
Intervention: Switch strategy
Number of subjects: 269
Study: 19865631

Group type: EXPERIMENTAL
Intervention: Medical-grade calcium sulfate hemihydrate (MGCSH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No grafting material (control)
Number of subjects: 40
Study: 16923370

Group type: EXPERIMENTAL
Intervention: Child and parent safety education programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no injury prevention education)
Number of subjects: 0
Study: 15212845

Group type: EXPERIMENTAL
Intervention: Hippocampal volume (HcV)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Normalised HcV and intracranial volume (ICV)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Normalised brain volume (BV) and ICV
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Absolute volumetric measures of HcV and BV
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Widespread brain atrophy
Number of subjects: 105
Study: 11777630

Group type: EXPERIMENTAL
Intervention: Tailored chemotherapy (FEC: cyclophosphamide, epirubicin, 5‐fluorouracil)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard chemotherapy (CTCb: cyclophosphamide, thiotepa, carboplatin)
Number of subjects: 34
Study: 10728155

Group type: EXPERIMENTAL
Intervention: Body weight treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Body fat treatment (measured by anthropometrics)
Number of subjects: 11
Study: 8083704

Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy (12 alternating cycles of ifosfamide/doxorubicin and cis-platin/etoposide)
Number of subjects: 438

Group type: COMPARATOR
Intervention: 3-week chemotherapy (6 alternating cycles of cyclophosphamide/doxorubicin/vincristine and PE)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy
Number of subjects: 438

Group type: COMPARATOR
Intervention: 3-week chemotherapy
Number of subjects: 438
Study: 2670465

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (IV 200 to 300 mg twice daily, followed by oral 500 mg twice daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Ceftazidime (IV 1 to 2 g two to three times daily)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 122
Study: 59850

Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean daily dose 79 mg)
Number of subjects: 20
Study: 31241736

Group type: EXPERIMENTAL
Intervention: Medical doctors performing inguinal hernia repair with mesh
Number of subjects: 242

Group type: COMPARATOR
Intervention: Surgeons performing inguinal hernia repair with mesh
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Medical doctors
Number of subjects: 242

Group type: COMPARATOR
Intervention: Surgeons
Number of subjects: 242
Study: 29132482

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical Muscle Stimulation (EMS)
Number of subjects: 0